Inhibrx Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
INHIBRX BIOSCIENCES, INC.
/s/ Mark P. Lappe
Name: Mark P. Lappe
Title: Chief Executive Officer and Chairman
Date: March 17, 2025
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Mark P. Lappe | Chief Executive Officer and Chairman(principal executive officer) | March 17, 2025 |
| Mark P. Lappe | ||
| /s/ Kelly D. Deck, C.P.A. | Chief Financial Officer(principal financial officer andprincipal accounting officer) | March 17, 2025 |
| Kelly D. Deck, C.P.A. | ||
| /s/ Jon Faiz Kayyem, Ph.D. | Director | March 17, 2025 |
| Jon Faiz Kayyem, Ph.D. | ||
| /s/ Douglas G. Forsyth | Director | March 17, 2025 |
| Douglas G. Forsyth | ||
| /s/ Kimberly Manhard | Director | March 17, 2025 |
| Kimberly Manhard | ||
| /s/ Kristiina Vuori, M.D., Ph.D. | Director | March 17, 2025 |
| Kristiina Vuori, M.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.